RIAS
TGTX icon

Rachor Investment Advisory Services’s TG Therapeutics TGTX Stock Holding History

Rachor Investment Advisory Services’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15
Closed -$448 – 491
2025
Q4 		$448 Buy
+15
New +$490 ﹤0.01% 354

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Rachor Investment Advisory Services's TGTX Position: Q1 2026 in Review

Rachor Investment Advisory Services sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 15 shares — an estimated $448 sold.

Rachor Investment Advisory Services first reported a position in TGTX in Q4 2025 and held it in 1 quarter. The position peaked at $448 in Q4 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Rachor Investment Advisory Services reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Rachor Investment Advisory Services sold 15 TG Therapeutics shares in Q1 2026, an estimated $448.
  • Rachor Investment Advisory Services first reported a position in TG Therapeutics in Q4 2025 and held it in 1 quarter.
  • Rachor Investment Advisory Services's TG Therapeutics position peaked at $448 in Q4 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Rachor Investment Advisory Services's 13F filing for Q1 2026, filed 7 May 2026.